Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2012

View Archived Issues

Phase I and II data presented for semaglutide

Zalypsis ineffective in urothelial carcinoma

Genentech begins phase II trials of ADCs based on Seattle Genetics technology

Preliminary results given for TH-302 with bevacizumab in glioblastoma

In vitro, in vivo and phase I data on DS-8587 presented

Synageva BioPharma patents novel polypeptides

City of Hope discloses new siRNA systems for HIV

Researchers at Takeda Pharmaceutical design novel PDE10A inhibitors

Significant reduction of HbA1c seen with VRS-859 in clinical trial

New GCS activators synthesized by Boehringer Ingelheim

New LTA mimetics divulged by scientists in Germany and The Netherlands

Zafgen presents novel MetAP 2 inhibitors for obesity

Novavax begins phase II RSV vaccine study in women of childbearing age

Enrollment continues in Can-Fite BioPharma's phase II/III psoriasis study

U.K. authorities clear phase I malaria vaccine trial with Isconova's adjuvant Matrix-M

Aeras and GSK enter agreement on tuberculosis vaccine development

Phase I ACP-501 study meets primary endpoint in stable atherosclerosis

New NICE guidance on Crohn's disease released

Crucell signs agreement to use Mucosis' platform for vaccine program

Researchers find possible biomarker for renal cell carcinoma

MedGenesis obtains new grant to develop glial cell line product

Oxford BioMedica provides update on TroVax development

Merck & Co. plans to initiate North American HDM AIT study

Canadian commercialization agreement set for MoxDuo

Cleveland BioLabs and Incuron announce start of phase I trial of CBLC-137

Navidea provides update on Lymphoseek NDA

FDA grants QIDP designation to radezolid

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...